Literature DB >> 33871726

Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Skorn Ponrartana1,2, Michael M Moore3, Sherwin S Chan4,5, Teresa Victoria6, Jonathan R Dillman7,8, Govind B Chavhan9,10.   

Abstract

Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. We focus particular attention on acute adverse reactions, nephrogenic systemic fibrosis and gadolinium deposition. We also discuss the non-GBCA MRI contrast agent ferumoxytol, which is increasing in use and has its own risk profile. Finally, we identify special populations at higher risk of harm from GBCA administration.

Entities:  

Keywords:  Adverse reaction; Children; Gadolinium deposition; Gadolinium-based contrast agent; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Safety

Year:  2021        PMID： 33871726     DOI： 10.1007/s00247-020-04896-7

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN： 0301-0449


  81 in total

1.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

2.  Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.

Authors:  Andrew G Bleicher; Emanuel Kanal
Journal:  AJR Am J Roentgenol       Date:  2008-12       Impact factor: 3.959

3.  Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.

Authors:  Robert J McDonald; Jennifer S McDonald; David F Kallmes; Mark E Jentoft; David L Murray; Kent R Thielen; Eric E Williamson; Laurence J Eckel
Journal:  Radiology       Date:  2015-03-05       Impact factor: 11.105

4.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

Review 5.  Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.

Authors:  Mahan Mathur; Jason R Jones; Jeffrey C Weinreb
Journal:  Radiographics       Date:  2019-12-06       Impact factor: 5.333

Review 6.  Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.

Authors:  Stephanie Holowka; Manohar Shroff; Govind B Chavhan
Journal:  Indian J Pediatr       Date:  2019-02-22       Impact factor: 1.967

Review 7.  Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.

Authors:  J Ramalho; R C Semelka; M Ramalho; R H Nunes; M AlObaidy; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-10       Impact factor: 3.825

8.  Work in progress: potential oral and intravenous paramagnetic NMR contrast agents.

Authors:  V M Runge; R G Stewart; J A Clanton; M M Jones; C M Lukehart; C L Partain; A E James
Journal:  Radiology       Date:  1983-06       Impact factor: 11.105

9.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.

Authors:  Tomonori Kanda; Kazunari Ishii; Hiroki Kawaguchi; Kazuhiro Kitajima; Daisuke Takenaka
Journal:  Radiology       Date:  2013-12-07       Impact factor: 11.105

Review 10.  25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives.

Authors:  Jessica Lohrke; Thomas Frenzel; Jan Endrikat; Filipe Caseiro Alves; Thomas M Grist; Meng Law; Jeong Min Lee; Tim Leiner; Kun-Cheng Li; Konstantin Nikolaou; Martin R Prince; Hans H Schild; Jeffrey C Weinreb; Kohki Yoshikawa; Hubertus Pietsch
Journal:  Adv Ther       Date:  2016-01-25       Impact factor: 3.845
View more
  1 in total

1.  The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients.

Authors:  Elnaz Asadollahzade; Fereshteh Ghadiri; Zahra Ebadi; Abdorreza Naser Moghadasi
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-08       Impact factor: 1.712
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.